Enabling The Cure of 100 Rare Diseases in 10 Years

CENTOGENE is the unique and essential partner for patients, physicians, and biopharma, from diagnostics to discovery to clinical development to market access & expansion in rare, metabolic, and neurodegenerative diseases.

>650,000

Individuals in the CENTOGENE Biodatabank

>400,000

Collected biosamples

29,000

Active physicians in our network

>19,000

Genes covered in testing portfolio

Working together with our patients, physicians, and partners to diagnose, understand, and treat rare, metabolic, and neurodegenerative diseases.

About our company

Diagnose.

CENTOGENE Baby Hand image reference nathan-dumlao-EytWx3BOrwI-unsplash

Diagnose.

To create a map, we integrate omic data from patients with the same disease to form an atlas representing a comprehensive collection of unique and detailed clinical and biochemical information about each rare disease.

Learn more

Understand.

CENTOGENE Why Choose Header Helix DNA

Understand.

Understanding the details of disease pathways – faulty genes and how they affect associated proteins, and how that leads to specific symptoms – can provide our pharmaceutical partners with valuable clues on how best to research treatments, by developing a drug to target specific molecules along disease pathways for example.

Learn more

Treat.

CENTOGENE Operationalising Clinical Trials Laboratory Scene

Treat.

The combination of omic technologies can identify drugs and drug targets with greater certainty, reducing the risk of failure and making drug development for rare diseases more financially attractive to pharma. Our goal: to enable the cure of 100 diseases in 10 years.

Learn more

Top Company News

CENTOGENE Announces Appointment of Miguel Coego Rios as Chief Financial Officer

Interim CFO Miguel Coego Rios appointed as Managing Director and permanent CFO. Centogene N.V. today announced the appointment of Miguel Coego Rios as…

Read more

CENTOGENE Announces Shareholder Approval of All Resolutions at 2022 Annual General Meeting

Centogene N.V. today announced the voting results of the Company’s Annual General Meeting. Shareholders voted in favor of all proposals, which…

Read more

CENTOGENE and Agios Expand Partnership for Clinical Development of PYRUKYND® (mitapivat) to Treat Children With Rare Blood Disease

Working together on the world’s first treatment that targets the underlying causes of pyruvate kinase (“PK”) deficiency in children under the age of…

Read more

Visit Our Online Ordering Portal

CentoPortal® is a user-friendly, online, web-based ordering portal designed to assist you at every step of processing your patients' samples.

Go to CentoPortal

CENTOGENE CentoPortal Logo